Immutep (ASX:IMM; NASDAQ:IMMP), a leading biotechnology firm specialising in LAG-3 immunotherapy, has achieved a significant milestone in its quest to redefine cancer treatment. Today, the company announced positive feedback from the US Food and Drug Administration (FDA) regarding its planned TACTI-004 Phase III trial of eftilagimod alfa (efti), a novel LAG-3 therapy. The TACTI-004 trial […]
Immutep receives positive FDA feedback Read More »
Astute Metals (ASX:ASE) has announced that the second batch of assays has delivered further high-grade intersections of lithium at the Red Mountain lithium project in Nevada, USA. These intersections are +80m in thickness. Shares are tarding 48.65 per cent higher at 5.5 cents. Aumake (ASX:AUK) has entered into a strategic procurement framework with Chinese SOE
Stocks of the Hour: Astute Metals, Aumake, EV Resources Read More »
Australian shares fell 0.8% at the open, influenced by upcoming US tech earnings and President Joe Biden’s decision to end his re-election campaign. The S&P/ASX 200 Index dropped by 62.5 points to 7909.1, with significant losses in materials and energy sectors. Alphabet and Tesla are expected to report their quarterly earnings later today, while US
ASX down 0.8% at noon: Investors react to Biden’s withdrawing from presidential race Read More »
Woodside (ASX:WDS) has announced its acquisition of the small U.S. LNG company Tellurian for what appears to be a very costly $1.2 billion. This price is considered high because Woodside states that the implied value is $1.2 billion, translating to a per-share price of $1.00. In contrast, Tellurian’s closing price on Friday was $0.57, with
Woodside acquires Tellurian for $1.2 billion Read More »
